Credit Suisse First Boston
VC Fund
Zurich, Switzerland
Credit Suisse First Boston is a VC fund in Zurich focused on Internet and Biotechnology. Credit Suisse First Boston (informally CSFB) was the investment banking division of Credit Suisse Group, prior to 2006. It was active in investment banking, capital markets and financial services.
- Total investments:
- 24
- Last investment:
- Lead investor:
- 8%
Last updated:
For AI agents: llms.txt
Industries Credit Suisse First Boston invests in
Stages Credit Suisse First Boston invests in
Countries Credit Suisse First Boston invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
John Bottega
|
|||
Lawrence M. Schloss
|
|||
|
Marc Granetz
|
|||
2 more contacts available
Investment Focus
Industry
- Internet 7 (29%)
- Biotechnology 4 (17%)
- Manufacturing 4 (17%)
- Health Care 3 (13%)
- Service Industry 3 (13%)
Stage
- Funding Round 9 (38%)
- Series B 4 (17%)
- Series C 4 (17%)
- Private Equity 2 (8%)
- Series E 1 (4%)
Country
- United States 16 (67%)
- United Kingdom 2 (8%)
- Canada 1 (4%)
- Bermuda 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
John Bottega
Director
|
Director | Total investments: 0 | Find email | |
|
Lawrence M. Schloss
Global Head and Chairman
|
Global Head and Chairman | Total investments: 0 | Find email | |
|
Marc Granetz
M&A Chief
|
M&A Chief | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
PTC Therapeutics
|
PTC Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of orally administered and small-molecule drugs. It offers Ataluren, an orally administered small-molecule investigational new drug for the treatment of cystic fibrosis and duchenne muscular dystrophy caused by nonsense mutations. Thecompany also provides PTC299, an anti-angiogenesis drug for the treatment of metastatic breast cancer, multiple tumors, and neurofibromatosis. Its products are used for the treatment of genetic disorders, oncology, and infectious diseases. PTC Therapeutics, Inc. was founded in 1998 and is based in South Plainfield, New Jersey. | $10M / Series F / Feb 05, 2007 | |
CELLFOR
|
CellFor is the world's leading independent supplier of high technology seedlings to the global forest industry. Using plant biotechnology, which is the use of biological processes to manufacture products, CellFor identifies and produces genetically superior conifer seedlings without genetic modification. | $4.6M / Oct 22, 2006 | |
Sunesis Pharmaceuticals
|
Sunesis is an emerging biopharmaceutical company creating new medicines to improve the lives of people with cancer. They are building a pipeline of drugs that selectively block critical mechanisms required for tumor growth and survival. The fight against cancer is an enormous mission that requires an integrated approach fueled by a commitment toinnovation. | $14M / Series C / Sep 16, 2004 | |
|
PTC Therapeutics
|
PTC Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of orally administered and small-molecule drugs. It offers Ataluren, an orally administered small-molecule investigational new drug for the treatment of cystic fibrosis and duchenne muscular dystrophy caused by nonsense mutations. Thecompany also provides PTC299, an anti-angiogenesis drug for the treatment of metastatic breast cancer, multiple tumors, and neurofibromatosis. Its products are used for the treatment of genetic disorders, oncology, and infectious diseases. PTC Therapeutics, Inc. was founded in 1998 and is based in South Plainfield, New Jersey. | $15M / Series E / Jun 23, 2004 | |
|
PTC Therapeutics
|
PTC Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of orally administered and small-molecule drugs. It offers Ataluren, an orally administered small-molecule investigational new drug for the treatment of cystic fibrosis and duchenne muscular dystrophy caused by nonsense mutations. Thecompany also provides PTC299, an anti-angiogenesis drug for the treatment of metastatic breast cancer, multiple tumors, and neurofibromatosis. Its products are used for the treatment of genetic disorders, oncology, and infectious diseases. PTC Therapeutics, Inc. was founded in 1998 and is based in South Plainfield, New Jersey. | $35M / Series E / Jan 07, 2004 | |
Aspen Insurance Holdings Limited
|
Aspen Insurance Holdings Limited is a company in the industry, with assets of $10.2 billion at the year ended December 31, 2013 and over 900 employees in eight countries. Founded in 2002, Aspen has been listed on the New York Stock Exchange since 2003 (NYSE:AHL). | $586.6M / Private Equity / Jun 01, 2002 | |
Oblix
|
As of March 28, 2005, Oblix, Inc. was acquired by Oracle Corp. The company develops identity-based security solutions for e-business networks. It offers Oblix NetPoint, a Web access management solution that provides an identity infrastructure for e-business environment. The company offers identity and Web services management, as well as accesscontrol and single sign-on to the enterprise and partner applications. Oblix, Inc. was founded in 1996 and is based in Cupertino, California. | $40M / Jan 02, 2002 | |
Sabeus Photonics
|
Sabeus Photonics optical devices and expand manufacturing facilities. Sabeus supplies optical communications components. | $16M / Series C / Dec 11, 2001 | |
iolon, inc.
|
iolon, Inc., is a privately held optical networking components company. The company provides high performance tunable devices for advanced fiber optic networks. iolon s initial product is a high-powered, external cavity, tunable laser source ideal for high bit rate, long haul applications. Future product lines include tunable filters, opticalswitches, polarization controllers, spectral monitors and universal transponders. iolon s platform technology enables advanced automation for high volume manufacturing based on patented micro-optics, MEMS and advanced servo control technologies. | $53M / Series B / Mar 01, 2001 | |
TrueSAN Networks
|
Founded in 1999, the company delivers enterprise storage networking systems, software and services for building scalable, intelligent, and universally accessible storage infrastructures. TrueSAN's next-generation storage solutions are designed to meet the unrelenting and unpredictable demand to store endless amounts of data. TrueSAN'stechnology provides unparalleled scalability, versatility, ease of use, as well as lower cost. | $30M / Series B / Jan 17, 2001 | |
| See all 24 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Credit Suisse First Boston invest in?
Credit Suisse First Boston invests primarily in Internet, Biotechnology and Manufacturing startups, most often at Funding Round and Series B stage. Most of the 24 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Credit Suisse First Boston?
Public channels for Credit Suisse First Boston include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Credit Suisse First Boston?
The team at Credit Suisse First Boston includes John Bottega (Director), Lawrence M. Schloss (Global Head and Chairman) and Marc Granetz (M&A Chief). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
